Table 1.
Characteristics of the RCTs included in this meta-analysis.
| First Author (Year) | Tumor Type | Treatment Arm | Injection Mode | Age (Years) | Male, No. (%) |
|---|---|---|---|---|---|
| Andtbacka 2015 [26] | Melanoma | T-VEC vs. GM-CSF | IT | EG: median 63 (22–94) CG: median 64 (26–91) |
EG: 173/295 (59%) CG: 77/141 (55%) |
| Bernstein 2018 [28] | Breast cancer | Pelareorep + paclitaxel vs. paclitaxel | IV | EG: median 61 (44–78) CG: median 57 (36–73) |
EG: 0/36 (0%) CG: 0/38 (0%) |
| Bradbury 2018 [29] | Non-small cell lung cancer | Pelareorep + chemotherapy vs. chemotherapy | IV | EG-1: median 63 (43–78) EG-2: 64 (23–77) CG-1: median 65 (39–80) CG-2: 64 (41–84) |
EG: 36/77 (47%) CG: 41/75 (55%) |
| Chesney 2018 [27] | Melanoma | T-VEC + ipilimumab vs. ipilimumab | IT | EG: median 65 (23–93) CG: median 64 (23–90) |
EG: 62/98 (63%) CG: 55/100 (55%) |
| Cohn 2017 [30] | Ovarian, tubal, or peritoneal cancer | Pelareorep + paclitaxel vs. paclitaxel | IV | NR | EG: 0/54 (0%) CG: 0/54 (0%) |
| Eigl 2018 [31] | Prostate cancer | Pelareorep + docetaxel vs. docetaxel | IV | EG: median 69.1 (50.3–83.7) CG: median 68.6 (49.7–86.6) |
EG: 21/21 (100%) CG: 23/23 (100%) |
| Freytag 2014 [34] | Prostate cancer | Ad5-yCD/mutTKSR39rep-ADP + IMRT vs. IMRT | IT | EG: mean 68.0 (55–78) CG: mean 65.2 (51–79) |
EG: 41/41 (100%) CG: 44/44 (100%) |
| Jonker 2018 [32] | Colorectal cancer | Pelareorep + FOLFOX6/bevacizumab vs. FOLFOX6/bevacizumab | IV | EG: median 60 (34–79) CG: median 59 (31–78) |
EG: 19/51 (37%) CG: 21/52 (40%) |
| Moehler 2019 [35] | Hepatocellular carcinoma | Pexa-Vec + BSC vs. BSC | IV | EG: mean 60 ± 11 CG: mean 55 ± 12 |
EG: 72/86 (84%) CG: 33/43 (77%) |
| Noonan 2016 [33] | Pancreatic adenocarcinoma | Pelareorep + paclitaxel/carboplatin vs. paclitaxel/carboplatin | IV | EG: median 61.5 (39–84) CG: median 66 (45–81) |
EG: 22/36 (61.1%) CG: 19/37 (51.4%) |
| Schenk 2020 [19] | Small cell lung cancer | NTX-010 vs. placebo | IV | EG: median 67 (44–81) CG: median 60 (50–82) |
EG: 14/26 (53.9%) CG:10/24 (41.7%) |
EG, experimental group; CG, control group; NR, not reported; BSC, best supportive care; IMRT, intensity modulated radiation therapy; IT, intratumoral; IV, intravenous.